# Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

> **NCT00257166** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 238 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Ziprasidone oral capsules
- **DRUG:** placebo oral capsules

## Key facts

- **NCT ID:** NCT00257166
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257166, "Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00257166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*